I realize a few too many cocktails & wines I misread that W it's not up....
I'll fix it>
I'll fix it>
GBA Presents: House of Gummy-!
- Thread starter stonedinvestor
- Start date
RUH Roe Confirmed-!!!!! 
UP Wheels Up Experience Inc.
$1.12-0.19(-14.50%)4:00 PM 08/11/23
NYSE |$USD |Post-Market:$1.16+0.04(+3.48%)7:54 PM//
Wheels Up in talks with lenders as cash dwindles - report
UP Wheels Up Experience Inc.
$1.12-0.19(-14.50%)4:00 PM 08/11/23
NYSE |$USD |Post-Market:$1.16+0.04(+3.48%)7:54 PM//
Wheels Up in talks with lenders as cash dwindles - report
Dichter resigned as CEO on May 9, 2023 amid losses with his pay package mentioned as contributing factor.[14] Dichter's departure arrangements were revealed in a May 9, 2023 Securities and Exchange Commission Form 8-K filing, which indicated will continue to receive his $950,000 annual salary for two years, he will remain a director on the company board, will receive a lump-sum payment of $3 million, plus a prorated annual bonus based on the number of days he was employed, continue to receive company health insurance coverage and 200 hours per year travel on Wheels Up aircraft, plus further benefits
This Guy we can trust!
TODD SMITHINTERIM CEO AND CFO
Todd Smithis WUP’s Interim CEO & Chief Financial Officer. In addition to his duties as Interim CEO, Mr. Smith oversees all aspects of the finance and accounting functions. Prior to WUP, Mr. Smith served as Global Head of Financial Planning and Analysis and Chief Financial Officer for GE Corporate. Over his career, he has served as Chief Financial Officer for several GE business units, including Gas Power Systems, Capital International, Healthcare Life Sciences, Capital Real Estate and Commercial Finance. Mr. Smith holds a B.S. in Business Administration from the University of Florida.
TODD SMITHINTERIM CEO AND CFO
Todd Smithis WUP’s Interim CEO & Chief Financial Officer. In addition to his duties as Interim CEO, Mr. Smith oversees all aspects of the finance and accounting functions. Prior to WUP, Mr. Smith served as Global Head of Financial Planning and Analysis and Chief Financial Officer for GE Corporate. Over his career, he has served as Chief Financial Officer for several GE business units, including Gas Power Systems, Capital International, Healthcare Life Sciences, Capital Real Estate and Commercial Finance. Mr. Smith holds a B.S. in Business Administration from the University of Florida.
I'm a conspiracy guy I admit it. But look who owns the most shares>
Shareholders
Name Equities %
DELTA AIR LINES, INC. 20.67 % 5,200,099 20.67 %
Kenneth Dichter 4.606 % 1,158,860 4.606 %
The Vanguard Group, Inc. 3.334 % 838,884 3.334 %
Todd Smith 1.979 % 497,948 1.979 %
Yea Big Kenny but they got Delta involved and with that leverage won't a bank turn over for them and give them a special life line....
Shareholders
Name Equities %
DELTA AIR LINES, INC. 20.67 % 5,200,099 20.67 %
Kenneth Dichter 4.606 % 1,158,860 4.606 %
The Vanguard Group, Inc. 3.334 % 838,884 3.334 %
Todd Smith 1.979 % 497,948 1.979 %
Yea Big Kenny but they got Delta involved and with that leverage won't a bank turn over for them and give them a special life line....
CAN YOU SMELL THE MONEY!!! Pretty sure I have saying this since early May.
You heard it then first.
The readers did too.
AMLX
So I was talking about the Europe final decision being big for the co.. but I realize now there is another trigger due to a very unusual situation...
It seems the first two trials of AMLX's compound for ALS went off so smashingly the FDA did the very rare move of Ok'ing before Phase 3<----
The Co agreed to do Phase 3 and that has not come out yet.<-- catalyst Big Time!
The drug is being sold and it is working patients are staying on it. I mean, could they pull a RAIN on me? Anything is possible but these guys actually are in people's bodies already, I really think the news will be great.
And that will double the stk instantly --it is severely held back here-
This is not a baby bio like Blue or something this is a $40 stk clearly. I think we have a good one here folks.
But last year,Amylyx Pharmaceuticals(NASDAQ:AMLX) achievedFDA approvalfor its ALS drug Relyvrio, despite not having phase 3 clinical trial results. ALS’s severity likely drove the FDA to its decision. Amylyx isalready generating revenuefrom Relyvrio.
The FDA demanded that Amylyx promise towithdraw the drugif that trial yields negative results. Relyvrio is also approved in Canada on aconditional basiswhich can be withdrawn based on the trial results. Amylyx faces an uncertain future, which may be causing its stock price to be held back until that uncertainty is resolved.
Besides Relyvrio, Amylyx hasnothing else in clinical trials. But if Relyvrio is an ALS success, it will not only pave the way for the worldwide roll-out, but also bolster the company’s attempts to get Relyvrio approved for other diseases.
The bottom line is that Amylyx has had a big win, but it needs to keep winning to stay in the game. If you like their science and their drug though, this is one of the most promising neurodegenerative biotech stocks to buy.
So I was talking about the Europe final decision being big for the co.. but I realize now there is another trigger due to a very unusual situation...
It seems the first two trials of AMLX's compound for ALS went off so smashingly the FDA did the very rare move of Ok'ing before Phase 3<----
The Co agreed to do Phase 3 and that has not come out yet.<-- catalyst Big Time!
The drug is being sold and it is working patients are staying on it. I mean, could they pull a RAIN on me? Anything is possible but these guys actually are in people's bodies already, I really think the news will be great.
And that will double the stk instantly --it is severely held back here-
This is not a baby bio like Blue or something this is a $40 stk clearly. I think we have a good one here folks.
But last year,Amylyx Pharmaceuticals(NASDAQ:AMLX) achievedFDA approvalfor its ALS drug Relyvrio, despite not having phase 3 clinical trial results. ALS’s severity likely drove the FDA to its decision. Amylyx isalready generating revenuefrom Relyvrio.
The FDA demanded that Amylyx promise towithdraw the drugif that trial yields negative results. Relyvrio is also approved in Canada on aconditional basiswhich can be withdrawn based on the trial results. Amylyx faces an uncertain future, which may be causing its stock price to be held back until that uncertainty is resolved.
Besides Relyvrio, Amylyx hasnothing else in clinical trials. But if Relyvrio is an ALS success, it will not only pave the way for the worldwide roll-out, but also bolster the company’s attempts to get Relyvrio approved for other diseases.
The bottom line is that Amylyx has had a big win, but it needs to keep winning to stay in the game. If you like their science and their drug though, this is one of the most promising neurodegenerative biotech stocks to buy.
VZ!!!!!!! And of course, we continue to work diligently to complete the PHOENIX trial with top line results anticipated in mid-2024.